利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

1149 条记录 (耗时 0.049 秒)

    Substituted triazolobenzodiazepines
    82.
    发明授权
    Substituted triazolobenzodiazepines 有权

    公开(公告)号：US10357499B2

    公开(公告)日：2019-07-23

    申请号：US16025512

    申请日：2018-07-02

    申请人： Concert Pharmaceuticals, Inc.

    发明人： Scott L. Harbeson

    IPC分类号： A61K31/551 ,  A61K31/5517 ,  A61K45/06 ,  C07D487/04 ,  C07B59/00

    摘要： This invention relates to novel substituted triazolobenzodiazepines of the Formula I: wherein each of the variables are defined herein and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering I-BET762.

    Therapeutic compositions for diabetic symmetrical polyneuropathy
    85.
    发明授权
    Therapeutic compositions for diabetic symmetrical polyneuropathy 有权

    公开(公告)号：US10307428B2

    公开(公告)日：2019-06-04

    申请号：US13877619

    申请日：2011-10-24

    申请人： Paul Fernyhough ,  Nigel A. Calcutt ,  Lakshmi Kotra

    发明人： Paul Fernyhough ,  Nigel A. Calcutt ,  Lakshmi Kotra

    IPC分类号： A61K31/496 ,  A61K31/5517 ,  A61K31/5513 ,  C07D417/12 ,  A61K31/46

    摘要： Compositions for therapy of a diabetic symmetrical polyneuropathy a subject in need thereof, the compositions comprising: an effective amount of a muscarinic acetylcholine receptor antagonist exemplified by pirenzepine, telenzepine, atropine, or derivatives thereof or salts thereof or analogs thereof or derivatives thereof, and a pharmacologically acceptable carrier. The composition may be injectable or alternatively, may be applied topically or alternatively, may be delivered orally. A suitable topical composition may comprise a lotion, a cream, a gel, or a viscous fluid. The muscarinic acetylcholine receptor antagonist may be a muscarinic acetylcholine receptor antagonist salt or a muscarinic acetylcholine receptor antagonist derivative or a muscarinic acetylcholine receptor antagonist analog.

    V1A antagonists to treat phase shift sleep disorders
    87.
    发明授权
    V1A antagonists to treat phase shift sleep disorders 有权

    公开(公告)号：US10265327B2

    公开(公告)日：2019-04-23

    申请号：US15065574

    申请日：2016-03-09

    申请人： Hoffmann-La Roche Inc.

    发明人： Patrick Schnider ,  Christophe Grundschober

    IPC分类号： C07D487/04 ,  A61K31/5517

    摘要： This invention relates to a new medical use for certain chemical compounds and pharmaceutical compositions containing them. The invention relates to compounds which are selective V1a antagonists for use in the treatment of phase shift sleep disorders, in particular jetlag. In another aspect, the invention relates to a pharmaceutical composition for use in the treatment of phase shift sleep disorders comprising a compound according to the invention and a pharmaceutically acceptable carrier.